Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

the Effect of Novel Antidiabetic Drug Combined With Angiotensin Receptor/Neprilysin Inhibitor Over Monotherapy on Urinary Protein in Patients With Type 2 Diabetes

NCT05922852 is registered in ClinicalTrials.gov with Peking University Third Hospital as lead sponsor.

NCT NCT05922852
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05922852 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
the Effect of Novel Antidiabetic Drug Combined With Angiotensin Receptor/Neprilysin Inhibitor Over Monotherapy on Urinary Protein in Patients With Type 2 Diabetes
Lead sponsor
Peking University Third Hospital
Phase
Observational
Overall status
Unknown status
Start date
March 1, 2023
Completion date
February 28, 2024
Enrollment
1,000 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

antidiabetic drugs, type 2 diabetes